News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Crucell N.V. (CRXL) Signs Commercial PER.C6 License Agreement With SingVax Pte Ltd For Vaccines Against Japanese Encephalitis


10/19/2005 5:13:05 PM

LEIDEN, Netherlands, March 22, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Nasdaq:CRXL) (Euronext:CRXL) today announced the signing of a commercial PER.C6(R) license agreement with Singapore-based company SingVax Pte Ltd for the development and commercialisation of new vaccines against Japanese encephalitis. Under the agreement, SingVax will focus on the development and commercialisation of a Japanese encephalitis vaccine for the endemic population as well as for travellers to the Asia Pacific region.

Read at Prime Zone


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES